Form 4: Vaxart Director Elaine Heron Reports Significant Equity Grants

Vaxart, Inc. Director Elaine J. Heron reported the acquisition of 16,000 common shares and 95,400 stock options through equity grants, increasing her beneficial ownership in the company.

Summary

• Elaine J. Heron, a Director of Vaxart, Inc. (VXRT), reported the acquisition of 16,000 shares of common stock and 95,400 stock options.
• The 16,000 common shares were granted upon the vesting of restricted stock units at a price of $0.
• The 95,400 stock options were granted with an exercise price of $0.7 per share at a price of $0.
• Both the common shares and the stock options are set to vest on the earlier of the date immediately prior to the 2026 annual meeting of stockholders or June 13, 2026, which is the first anniversary of the grant date.
• Following these transactions, Ms. Heron beneficially owns 56,566 shares of common stock and 95,400 stock options directly.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The grants represent a standard form of director compensation and align the director's interests with shareholders, which is generally viewed favorably. There are no negative transactions (e.g., sales) reported.

Positives

• The grant of 16,000 common shares and 95,400 stock options to a director indicates continued alignment of management interests with shareholder value.
• The acquisition of equity by a director can be seen as a vote of confidence in the company's future prospects.

Negatives

• No explicit negatives are present in this Form 4 filing, which primarily reports equity grants.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

This Form 4 filing primarily reports past equity grants and does not contain explicit forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing is specific to an insider transaction at Vaxart, Inc. and does not provide broader industry trends or competitive analysis. It reflects standard compensation practices for directors in the biotechnology or pharmaceutical sector, where equity grants are common for aligning interests.

Comparison to Industry Standards

• This Form 4 filing details specific equity grants to a director of Vaxart, Inc. and does not provide information suitable for direct comparison to global benchmarks, specific comparable companies, projects, or results.
• Director compensation packages, including equity grants, vary widely across companies and industries based on size, performance, and compensation philosophy.

Related Party Transactions

• The grant of 16,000 common shares and 95,400 stock options to Elaine J. Heron, a Director of Vaxart, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with those of the shareholders, potentially encouraging decisions that enhance long-term shareholder value.
• Employees: No direct impact on employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Vesting of 16,000 common shares and 95,400 stock options on the earlier of the date immediately prior to the 2026 annual meeting of stockholders or June 13, 2026.
• Potential exercise of 95,400 stock options by June 13, 2035.

Key Dates

Keywords

Vaxart, VXRT, SEC Form 4, Insider Trading, Equity Grant, Stock Options, Restricted Stock Units, Director Compensation, Beneficial Ownership, Elaine J. Heron